Publication | Closed Access
Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer
51
Citations
38
References
1999
Year
Oral JM216 is active in previously untreated patients with SCLC and shows mild toxicities.
| Year | Citations | |
|---|---|---|
Page 1
Page 1